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Malignant gastric outlet obstruction is most commonly seen in the patients with cancers of the pancreas, gallbladder, biliary tree, stomach, and duo-
denum. The placement of self-expanding metal stents under ﬂuoroscopy or endoscopy has proven to be an alternative to surgical treatment and to have
the advantages of being less invasive, having a lower complication rate, and allowing a quicker recovery. In this review article, we provide an overview of
current ﬂuoroscopic and endoscopic stenting practice for gastric outlet obstruction with regard to stent design and stenting procedure, efﬁcacy, and
complications, and compare stenting and surgery.
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Malignant gastric outlet obstruction (GOO) is most commonly
seen in patients with cancers of the pancreas, gallbladder, biliary
tree, stomach, and duodenum. It has been reported that GOO occurs
in 15–20% of patients with pancreatic cancer.1,2 Patients with GOO
are often unable to take liquids or solid food and can have symp-
toms of nausea, vomiting, and severe weight loss.
Gastroenterostomy has traditionally been the treatment strat-
egy for this condition. However, it carries a high risk of complica-
tions (25–35%) and high perioperative mortality (2%),3–7 and many
patients are excluded from surgery because of poor medical con-
dition.8 The placement of self-expanding metal stents under ﬂuo-
roscopy or endoscopy has proven to be an alternative to surgical
treatment and to have the advantages of being less invasive, having
a lower complication rate, and allowing a quicker recovery.9–13
This article presents an overview of current ﬂuoroscopic and
endoscopic stenting practice for GOO with regard to stent design
and stenting procedure, efﬁcacy, and complications, and compares
stenting and surgery.
Stent design
Covered and uncovered
The main principle behind enteral stents is to provide internal
splinting of the lumenwith enough radial force to push against any
disease process obstructing the duodenal tract.14 Enteral stents canDepartment of Radiology, the First Afﬁliated Hospital of Nanjing Medical University, Nanjing
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are coated. The most commonly used materials for enteral stents
are silicone, polyurethane, and expanded polytetraﬂuoro-
ethylene.15 The advantage of covered stents is that they can prevent
tumor ingrowth, which can cause restenosis. However, they have
an unacceptably higher migration rate when used for malignant
GOO (21–26%) compared with bare-metal stents (0–3%).16–19
Another disadvantage of covered stents is that the delivery sys-
tem is larger in size and more rigid, making the stents difﬁcult to
deliver transorally to distant lesions, such as distal duodenal ste-
nosis, through tortuous anatomy.16 Moreover, there is an increased
incidence of biliary obstruction due to occlusion of the common
bile duct by the covered stent.19,20 In contrast, bare stents have a
low risk of migration and are ﬂexible enough for distal delivery, but
tumor ingrowth can be a problem and can result in stent occlusion.
Woo et al13 recommended using uncovered stents for duodenal
stenoses caused by pancreaticobiliary malignancies because of a
lower complication rate and longer stent patency. However, Bang
et al21 compared covered stents and uncovered stents formalignant
GOO in 134 patients and found that there were no signiﬁcant dif-
ferences between groups with respect to resumption of food intake
and improvement of overall performance score. In a study in which
a partially covered dual metal stent was reported to have good
outcomes in GOO,11 a migration rate of 4%, which is much lower
than that of covered stents and similar to that of bare stents, was
demonstrated. The diameter of the stent delivery system is 3.8 mm,
which is much smaller than a conventional covered-stent delivery
system (6.0 mm in diameter)., China
ng Medical University, 300 Guangzhou Road, Gulou District, Nanjing 210029, Chin
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Earlymetallic enteral stents weremade of stainless steel, such as
the Enteral Wallstent (Boston Scientiﬁc, Marlborough, MA, USA).
Although this stent had good radial force, it was prone to
straightening, which increases the risk of stent impaction, and
could not be followed up using magnetic resonance imaging. With
the invention of nitinol wire stents, stainless steel stents gradually
lost ground. Nitinol wire is soft and ﬂexible, and stents made of
nitinol demonstrate good radial and axial force, the combination of
which is felt to be more effective than either radial or axial force
alone.15
Stent delivery system
Enteral stents can be placed using a through the scope (TTS)
delivery system or an over-the-wire (OTW) delivery system.
Because a TTS delivery system requires going through the scope
channel, its proﬁle should be small. For this reason, the size of TTS
delivery systems is usually no more than 10F. There is no such
requirement for an OTW system, however, because stent placement
using this delivery system can be performed only under ﬂuoro-
scopic guidance. The disadvantage of OTW systems is that, because
the lesion cannot be directly seen under ﬂuoroscopy, traversing the
stricture can be time-consuming.
Stents designed for distal duodenal obstruction
The distal duodenum has three segments: the second half of the
horizontal segment, the ascending segment, and the duodenoje-
junal ﬂexure. A distended stomach and a long distance to a distal
duodenal stenosis can make delivery of a traditional enteral stent
difﬁcult.11,22 The ideal stent for this region should have enough
radial force to overcome a tortuous stricture and enough ﬂexibility
to pass through tortuous areas without kinking. The stent delivery
system should be long enough to reach the target but small enough
to allow smooth delivery of the stent.
A newly designed stent and delivery system designed for distal
duodenal stenosis was recently introduced and has shown a good
technical success in a preliminary case study.23 The stent wires are
braided in a nested conﬁguration, which provides better radial
force than the traditional helical form. The closed-loop design at
both ends of the stent minimizes the possibility of injury to adja-
cent tissues, and its dumbbell shape reduces the risk of migration.
The delivery system has a small diameter (10F) and a long length
(2300 mm). The inner layer of the sheath is strengthened by a
metallic mesh layer, which can prevent the system from kinking
when winding toward a distal lesion.
Stenting procedure
Fluoroscopic technique
An aerosol spray for topical anesthesia of the pharynx is
routinely administered before the procedure. A 0.89-mm exchange
guidewire is advanced through the mouth and across the stricture
to the distal portion of the duodenum or jejunum. A coil catheter
(consisting of a distal uncovered andmiddle covered coil part, and a
proximal homeostasis valve part with side holes) or a 5F multi-
purpose catheter is inserted over the guidewire to the distal part of
the stricture to measure its length. The catheter is then exchanged
for the stent delivery system, and the stent is delivered under
ﬂuoroscopic guidance. The stent should be 3–4 cm longer than the
stricture to ensure that the stent covers the entire lesion. For
duodenal stenting, prestent balloon dilation is discouraged becauseit increases the risk of bowel perforation and stent displacement or
migration.18 The exception to this is when a very tight lesion pre-
vents the stent delivery system from advancing, in which case
predilatation with a 10-mm balloon should be performed.14 The
stent is usually fully expanded 1–2 days after placement, so post-
placement dilatation is not normally performed.
In distal duodenal stenosis, stomach distension makes it very
difﬁcult to advance the stent delivery system to the target lesion
because of loops that can be created by the guidewire and delivery
system in a distended stomach. To reduce the possibility of looping,
it is recommended that the stomach be decompressed with a
nasogastric tube at least 24 h before the procedure.24 A guiding
sheath that assists stent placement in patients with malignant GOO
has been described by Park et al.25 The sheath can help overcome
the problem of guidewire looping, and the overall technical success
rate was 98%. The authors also found that patients with pancreatic
cancer and duodenal stenosis were signiﬁcantly more likely to
require the use of guiding sheaths. Moreover, for distal duodenal
stenosis, a long, super-stiff guidewire may be required to provide
enough support during negotiation of the stenosis and stent
delivery.
Endoscopic technique
Conscious sedation is performed before the start of the proce-
dure. Because of the size of the TTS delivery system, an operative
endoscope is required. The endoscope is ﬁrst advanced through the
stricture, and a guidewire is then inserted through the working
channel of the endoscope. The tip of the guidewire should be at
least 20 cm distal to the stricture, and the stent length is the same
as in ﬂuoroscopic stent placement. The stent delivery system is
then advanced over the guidewire to the lesion and deployed. Stent
position and patency are conﬁrmed endoscopically and ﬂuoro-
scopically. As with the guiding sheath used in ﬂuoroscopic tech-
nique, the endoscope can prevent looping of the guidewire in the
stomach.
For extremely difﬁcult cases in which both transoral ﬂuoro-
scopic and endoscopic techniques have failed, enteral stenting via
the percutaneous transgastric route is an option.26 For example,
strictures in the distal portion of the duodenum or proximal
jejunum can be managedmore easily using this approach. It should
be mentioned that after successful stenting using this technique, a
gastrostomy tube should be placed and maintained for 10–15 days
to allow tract maturation and avoid leakage of gastric contents.16
Evaluation of efﬁcacy
Technical success is deﬁned as adequate positioning and
deployment of a stent across the stricture. The GOO Scoring System
(GOOSS) is used to evaluate the severity of GOO before and after
stent placement (0 ¼ unable to eat anything; 1 ¼ able to swallow
liquid only; 2¼ able to eat soft solids; 3¼ able to eat low-residue or
full diet).1 Clinical success is deﬁned as resolution of symptoms
and/or improvement of food intake as quantiﬁed by GOOSS.27 Re-
ported technical success rates are over 90%. The most common
reasons for failure are inability of the guidewire to traverse the
stricture, inability of the stent delivery system to reach the lesion,
failure of stent deployment, and early migration of the stent during
the procedure.27,28 Clinical success rates are not as high as those for
technical success. Depending on the deﬁnition of clinical success,
the reported rates range from 79% to 94%.11,29–31
In a systematic review conducted in 2004 that included 606
patients with gastroduodenal malignancies, rates of technical
success and clinical success (deﬁned as relief of symptoms) for
stent placement were 97% and 87%, respectively.32 Jeurnink et al27
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duodenal stenting and reported the rate of clinical success (deﬁned
as improvement of GOOSS) to be 89%. In a recent prospective
multicenter study, 108 adult patients with malignant GOO under-
went endoscopic duodenal stent placement.31 The technical suc-
cess rate was 99.1%; the rate of clinical success, deﬁned as relief of
symptoms and/or improvement of GOOSS, was 84.5%. Technical
failure in two patients was caused by stent deployment too far
distally in one patient, in whom a second stent was inserted during
the same procedure, and a long stricture, requiring two stents for
complete coverage, in the other. Kim et al11 prospectively studied
placement of partially covered dual stents under ﬂuoroscopic
guidance in 213 patients. They reported the technical and clinical
success rates to be 94% and 94%, respectively. The cause of technical
failures in 12 patients was inability to pass the guidewire or stent
delivery system through the stricture.
Complications
Complications can be classiﬁed as major and minor. Major
complications are deﬁned as severe and life-threatening and
include perforation, ﬁstula formation, stent migration, and hem-
orrhage. Minor complications are nonlife-threatening and include
mild pain, mild fever, and occasional vomiting without obstruc-
tion.27 Reported complication rates range from 0% to 30%. In the
study of 213 patients by Kim et al,11 the complication rate during
follow upwas 21%, with tumor overgrowth (7%), stent collapse (4%),
and stent migration (4%) being the most common complications.
Tumor overgrowth and stent collapse were remedied with addi-
tional stent placement in most patients. In the eight patients with
stent migration, three stents had partially migrated and treatment
was placement of an additional stent. Of the ﬁve patients with
complete stent migration, two patients, in whom the stents caused
intestinal obstruction, were treated with surgical removal. Because
the stent used was a partially covered dual stent, no tumor
ingrowth was reported. The authors also found that chemotherapy
after stent placement can increase the migration rate but is also
associated with an increase in the maintenance of stent patency. A
review of 32 studies from 1992 to 2003 conducted by Dormann
et al32 revealed no procedure-related mortality and identiﬁed stent
obstruction (18%) due mainly to tumor growth to be the most
common complication. Stent migration occurred in 5% of patients
and severe complications (bleeding and perforation) occurred in
1.2%. In another review, common major complications were stent
migration, stent dysfunction or occlusion, jaundice, and bleeding.27
In 2014, Tringali et al31 conducted a prospective multicenter study
of stent placement for malignant GOO. The complications observed
in their study were mostly stent-related and included stent
obstruction (15%) and migration (1.9%). Severe complications such
as bleeding (4.6%) and perforation (1.9%) were uncommon, and
there was no procedure-related mortality.
Stent placement versus surgical gastrojejunostomy
The aim of palliation of patients with malignant GOO is to
enable resumption of oral food intake by restoring gastrointestinal
continuity.33 Surgical gastrojejunostomy (GJ) has been the tradi-
tional standard treatment for these patients. However, GJ place-
ment is invasive and associated with added morbidity and
mortality.34,35 Moreover, many patients with malignant GOO are
poor surgical candidates because of tumor stage and/or perfor-
mance status. For these patients, ﬂuoroscopic or endoscopic
stenting provides a less invasive method.
Many studies have compared surgical GJ and stent placement,
and most are retrospective studies.27,32,33 To date there have beenonly three randomized controlled trials (RCTs) with small numbers
of patients.8,36,37 In the latest trial, with the largest number of pa-
tients, 18 patients underwent GJ and 21 patients underwent stent
placement.37 Results showed that food intake improved more
rapidly after stent placement than after GJ (5 days vs. 8 days,
P < 0.01), but long-term relief tended to be better after GJ (50 days
vs. 72 days, P ¼ 0.05). However, the stented group required more
reinterventions than the GJ group (10 vs. 2, P< 0.01). Therewere no
between-group differences in median survival and quality of life.
The mean costs of GJ, however, were higher than those of stent
placement.
In a recent systematic review published in 2014, the authors
collected and analyzed data from three RCTs and 14 non-RCTs for
patients who underwent surgical GJ or endoscopic stenting for
malignant GOO.33 They found that patients with stent placement
were more likely to tolerate oral food intake earlier and to leave the
hospital earlier than GJ patients. Complication rates were similar to
those of GJ patients, and there was no survival difference between
these twomethods. Total medical costs were higher in the GJ group.
With regard to survival time, however, some studies have
demonstrated that surgical GJ may be superior to stent place-
ment.6,38 No et al38 found that median survival was 189 days in the
stent group and 293 days in the GJ group; however, a high likeli-
hood of selection bias, as described by Goldberg,39 may have been a
factor, because patients with more advanced disease were more
likely to be in the stented group. Prospective randomized trials with
relatively large numbers of patients are needed to provide a
deﬁnitive answer.
Conclusion
Fluoroscopic or endoscopic stent placement has become the
mainstay of treatment for malignant GOO because it is minimally
invasive, safe, and cost-effective. Uncovered and covered stents
each have their own advantages and disadvantages. The choice of
stent should be individualized according to the characteristics of a
patient’s stricture and general condition. Compared with surgery,
stent placement can result in more rapid resumption of food intake,
fewer complications, and shorter hospital stays. GJ may be more
suitable for patients with resectable diseases and longer life ex-
pectancies, but this it is still being debated.
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